Open AccessEfficacy of a micronized, nanocrystal fenofibrate formulation in treatment of hyperlipidemia in dogs
Author(s) -
Munro Matthew J. L.,
Hulsebosch Sean E.,
Marks Stanley L.,
Gilor Chen
Publication year - 2021
Publication title -
journal of veterinary internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.356
H-Index - 103
eISSN - 1939-1676
pISSN - 0891-6640
DOI - 10.1111/jvim.16190
Subject(s) - fenofibrate , medicine , hyperlipidemia , hypertriglyceridemia , adverse effect , gastroenterology , creatinine , triglyceride , alkaline phosphatase , cholesterol , urology , endocrinology , diabetes mellitus , biochemistry , chemistry , enzyme
Background Safe, effective, and readily available drug therapies are required for the management of hyperlipidemia and its associated complications in dogs. Objectives To investigate the efficacy of a micronized, nanocrystal formulation of fenofibrate (Tricor) in the treatment of hyperlipidemia in dogs. Animals Ten client‐owned dogs with primary (n = 7) and secondary (n = 3) hyperlipidemia. All dogs had hypertriglyceridemia at baseline; 3 dogs also had hypercholesterolemia. Methods Prospective dose‐escalation study. Dogs were treated with fenofibrate orally once daily in up to 3 cycles of 21 days each. Fenofibrate dose was increased at the end of each cycle if hypertriglyceridemia persisted and adverse effects were not documented. Complete blood count, biochemistry, and urine protein:creatinine ratio were collected serially. Baseline (T0) parameters were compared to time of maximal reduction in serum triglyceride concentrations (T1) and reported as median (range). Results Triglycerides normalized in all dogs (T0 = 662 mg/dL [189‐2391]; T1 = 113 mg/dL [81‐132]; P = .002). Fenofibrate dose at T1 = 6.4 mg/kg PO q24h (range, 2.2‐13.5). T1 was achieved at 3 (n = 4), 6 (n = 4), and 9 (n = 2) weeks. Serum cholesterol concentrations decreased in 9 of 10 dogs. Quiet demeanor and firm stools in 1 dog were the only reported adverse reactions. Fenofibrate administration resulted in a significant reduction in median alkaline phosphatase activity ( P = .049). Conclusions and Clinical Importance Over 21 to 63 days, TriCor was effective in the management of primary and secondary hyperlipidemia in dogs.